Novel kinase inhibitors in renal cell carcinoma: Progressive development of static agents

被引：7
|
作者：
Desai A.A. [1 ]
Stadler W.M. [1 ]
机构：
[1] Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637
来源：
Current Urology Reports | 2006年 / 7卷 / 1期
关键词：
Epidermal Growth Factor Receptor; Renal Cell Carcinoma; Bevacizumab; Clin Oncol; Sorafenib;
D O I：
10.1007/s11934-006-0033-x
中图分类号：
学科分类号：
摘要：
The rapidly expanding knowledge regarding neoplastic diseases is providing a plethora of new targets for drug discovery and development as exemplified by recent data in renal cell carcinoma. The initial experience with molecularly "targeted" agents has demonstrated that development of the newer non-cytotoxic agents will provide unique challenges requiring modification of many traditional drug development concepts and methods. We discuss recently reported data from a few renal cell carcinoma trials with putative cytostatic agents and highlight issues that need to be addressed for efficient development of cytostatic agents during various phases of clinical development. Copyright © 2006 by Current Science Inc.
引用
收藏
页码：16 / 22
页数：6
相关论文
共 50 条
  • [1] Novel kinase inhibitors in renal cell carcinoma: Progressive development of static agents
    Desai A.A.
    Stadler W.M.
    Current Oncology Reports, 2005, 7 (2) : 116 - 122
  • [2] Novel tyrosine kinase inhibitors for renal cell carcinoma
    Dorff, Tanya B.
    Pal, Sumanta K.
    Quinn, David I.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (01) : 67 - 73
  • [3] Protein kinase inhibitors in renal cell carcinoma
    Daste, Amaury
    Grellety, Thomas
    Gross-Goupil, Marine
    Ravaud, Alain
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (03) : 337 - 351
  • [4] Kinase inhibitors in the treatment of renal cell carcinoma
    Larkin, James M. G.
    Eisen, Tim
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 60 (03) : 216 - 226
  • [5] Tyrosine kinase inhibitors in renal cell carcinoma
    Potti, A
    George, DJ
    CLINICAL CANCER RESEARCH, 2004, 10 (18) : 6371S - 6376S
  • [6] Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma
    Bukowski, Ronald M.
    FRONTIERS IN ONCOLOGY, 2012, 2
  • [7] Update on novel agents in renal cell carcinoma
    Tamaskar, Ila
    Pili, Roberto
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (12) : 1817 - 1827
  • [8] Complete Remission With Tyrosine Kinase Inhibitors in Renal Cell Carcinoma
    Albiges, Laurence
    Oudard, Stephane
    Negrier, Sylvie
    Caty, Armelle
    Gravis, Gwenaelle
    Joly, Florence
    Duclos, Brigitte
    Geoffrois, Lionel
    Rolland, Frederic
    Guillot, Aline
    Laguerre, Brigitte
    Legouffe, Eric
    Kohser, Frederic
    Dietrich, Pierre-Yves
    Theodore, Christine A.
    Escudier, Bernard
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05) : 482 - 487
  • [9] Protein kinase inhibitors in the treatment of renal cell carcinoma:: sorafenib
    Bracarda, S.
    Caserta, C.
    Sordini, L.
    Rossi, M.
    Hamzay, A.
    Crino, L.
    ANNALS OF ONCOLOGY, 2007, 18 : 22 - 25
  • [10] Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma
    Bianchi, Loredana
    Rossi, Luigi
    Tomao, Federica
    Papa, Anselmo
    Zoratto, Federica
    Tomao, Silverio
    ENDOCRINE-RELATED CANCER, 2013, 20 (05) : R233 - R245
12345